Changing National and Regional Trends in Drug Use-Associated Infective Endocarditis From 2016 to 2022

Clicks: 7
ID: 337385
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #606 of 635 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 635 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Drug use-associated infective endocarditis (DUA-IE) is a life-threatening condition that has increased alongside opioid injection. Recent shifts in drug use patterns and access to harm reduction and addiction treatment necessitate updated national estimates to assess disease burden. METHODS: Using a representative sample of US hospitalizations from 2016 to 2022, we estimated national trends in DUA-IE hospitalizations among adults, stratified by year, drug category (opioids, stimulants, both, other), and census division. Logistic regression assessed the marginal probability of stimulant-associated endocarditis by individual (age, sex, race/ethnicity, insurance) and hospital characteristics (location/teaching status, bed size, census division). Analyses accounted for survey design and were weighted to provide national estimates. RESULTS: An estimated 118 190 DUA-IE hospitalizations occurred from 2016 to 2022, peaking in 2020 (n = 18 735) before declining annually through 2022 (n = 15 345). From 2016 to 2022, opioid-only hospitalizations decreased (49.4%-39.9%), while co-use of opioids and stimulants (22.6%-28.6%) and stimulant-only hospitalizations (14.7%-18.3%) increased. Regional trends varied, with stimulants surpassing opioids in several Western divisions. Logistic regression models showed rising probability of stimulant-involved DUA-IE, highest in Western divisions (Pacific: 0.59 [95% CI .56-.62] vs New England: 0.34 [95% CI .31-.38]). CONCLUSIONS: Drug use-associated infective endocarditis epidemiology is shifting, with overall hospitalizations declining but stimulant use emerging as a key driver, particularly in the Western United States. Current harm reduction and treatment efforts may be reducing DUA-IE hospitalizations, but targeted strategies addressing stimulant use are urgently needed.
Reference Key
openalex_W7223909385 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Paul J. Christine, Scott Fabricant, Ayesha Ashley Appa, Simeon D. Kimmel
Are you one of these authors? Claim your profile
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag607
URL
https://doi.org/10.1093/cid/ciag607
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.